Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 15 821 M
EBIT 2017 7 624 M
Net income 2017 -1 759 M
Debt 2017 17 074 M
Yield 2017 1,29%
Sales 2018 16 934 M
EBIT 2018 8 303 M
Net income 2018 -670 M
Debt 2018 16 454 M
Yield 2018 1,34%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 5,82x
EV / Sales2018 5,40x
Capitalization 74 939 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to branded... 
Sector
Pharmaceuticals
Calendar
05/31 | 03:00pmPresentation
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
05/16 CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in first quart..
05/16 ALLERGAN PLC : ex-dividend day
05/13 High-profile Snap stakeholders revealed in filings
05/13 High-profile Snap stakeholders revealed in filings
05/09DJALLERGAN : Thin Is In as Allergan Dodges Generics Bullet -- Heard on the Street
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/03DJPerrigo Says Investigators Searched Its Offices in Generic-Drug Probe
02/24 ALLERGAN PLC : ex-dividend day
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/13 Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 273 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC74 939
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results